Subcutaneous progesterone (Prolutex) versus vaginal (Cyclogest) for luteal phase support in IVF/ICSI cycles: a randomized controlled clinical trial

Middle East Fertility Society Journal

Table 2 Comparison of the ovarian stimulation outcomes between two groups

Variables	Group A (Prolutex) (n = 40)	Group B (Cyclogest) (n = 40)	p-value
Number of used gonadotropins (rFSH) ampoules	21.7 ± 5.9	22.6 ± 5.7	0.45
Duration of ovulation stimulation (day)	10.8 ± 2.3	11.3 ± 1.8	0.24
Total number of retrieved oocytes	8.7 ± 4.6	9.1 ± 3.9	0.69
Number of MII oocytes	7.1 ± 3.6	8.0 ± 3.6	0.27
The serum level of progesterone on hCG day (ng/ml)	0.78 ± 0.47	0.74 ± 0.50	0.44
The serum level of progesterone on ET day (ng/ml)	55.7 ± 8.1	55.0 ± 9.8	0.93
The number of transferred embryos	2.0 ± 0.5	2.0 ± 0.6	0.68
Endometrial thickness (mm)	5.1 ± 8/9	4.1 ± 7.9	0.88

rFSH, recombinant follicle-stimulating hormone; hCG, human chorionic gonadotropin; ET, embryo transfer. The data are presented as mean (± standard deviation). P-value less than 0.05, there was a significant difference between groups